Efficacy of screening for gynecologic malignancies by measuring urine-blood porphyrin concentration using oral 5-aminolevulinic acid

Not Applicable

Completed

• Conditions: malignant genital tumors benign gynecologic tumors

• Registration Number: JPRN-UMIN000008890
• Lead Sponsor: agoya University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10-01
• Study Completion: 2017-12-31
• Last Update Posted: 2023-10-17

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients (including tuberculosis activities) uncontrolled infection. 2)Patients with severe anamnesis (Malignant hypertension. With severe congestive heart failure. Severe liver failure. Myocardial infarction within 3 months. End-stage cirrhosis. Poorly controlled diabetes. Severe pulmonary fibrosis. Interstitial pneumonia activity) 3) Allogeneic bone marrow transplantation 4) Patients with severe mental disorders 5)Patients with porphyria or hypersensitivity to porphyrins allergy 6) A gravida, a lactational woman 7) Patients with severe anemia 8)Patients were deemed inappropriate by research investigators 9)Patients with malignant tumor during treatment. cancer patients within 5 years after treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified